Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 13/20 | 0.43 |
| ▸ | APP | P05067 | 3/20 | 0.36 |
| ▸ | PGR | P06401 | 6/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7890218 | 0.85 | BACE1 (0.57) | BACE1PGRAR | |
| SCHEMBL1465209 | 0.85 | BACE1 (0.57) | BACE1PGRAR | |
| SCHEMBL31036 | 0.85 | BACE1 (0.57) | BACE1PGRAR | |
| SCHEMBL30327 | 0.72 | TDP1 (0.38) | BACE1 | |
| SCHEMBL7882444 | 0.72 | TDP1 (0.38) | BACE1 | |
| SCHEMBL1465915 | 0.72 | BACE1 (0.69) | BACE1APPPGR | |
| SCHEMBL1464946 | 0.67 | BACE1 (0.58) | BACE1PGRAR | |
| SCHEMBL1464612 | 0.66 | BACE1 (0.60) | BACE1PGRAR | |
| SCHEMBL30303 | 0.66 | BACE1 (0.57) | BACE1PGRAR | |
| SCHEMBL30483 | 0.66 | BACE1 (0.59) | BACE1PGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336717-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, LLC (US) | 2019-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336717-B2 | Inhibitors of beta-secretase | BACE1, BACE2, PSEN1 | BACE1 1/4885APP 4/4885PGR 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.